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BACKGROUND Warfarin is commonly used for stroke risk reduction
in atrial ﬁbrillation (AF). While effective at reducing the risk of
ischemic stroke, it increases the risk of bleeding. Left atrial appendage
closure (LAAC) provides embolic protection and enables most patients
to discontinue lifelong oral anticoagulation (OAC). This analysis
sought to quantify the cost to the US Centers for Medicare & Medicaid
Services (CMS) of bleed-related complications with warfarin compared
to LAAC with the WATCHMAN.
METHODS A Markov model was developed to assess cost of bleeding
complications with LAAC versus warfarin from a CMS perspective over
a 20-year time horizon. Probabilities for major bleeding events were
determined from a pooled analysis of the PROTECT AF and PREVAIL
trials. For costing purposes, LAAC patients were assumed to adhere to
the OAC regimen in these study protocols. According to published
data, bleeding history and age were modeled to increase bleeding risk.
Bleed-related mortality risk was obtained from 2012 US HCUP data.
Costs of bleeds included direct costs due to in-patient care as well as
long-term disability costs. Cost data were taken from the literature
and 2015 US DRGs/CPTs.
RESULTS The procedural-related bleeding event rate with LAAC was
4.9%, with an average cost to CMS of $176 per patient. Modeled post-
procedural bleed event rates were 5.1% for LAAC compared to 11.5%
for warfarin. Hemorrhagic stroke accounted for 18% and 24% of these
bleed events for LAAC and warfarin, respectively. At 20 years, direct
costs for non-procedural bleeds were $3,111 per LAAC patient and
$9,244 per warfarin patient. On average, long-term disability costs
accounted for an additional $3,440 per LAAC patient and $10,502 per
warfarin patient. Total bleeding costs were $13,195 greater with
warfarin than LAAC.
CONCLUSIONS This analysis suggests that among AF patients at risk
for stroke, bleeding-related costs to CMS are nearly 3 times greater
with chronic warfarin compared to LAAC with WATCHMAN. This
should be considered when assessing the overall cost beneﬁt for non-
pharmacological, stroke risk reduction therapies in AF.
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BACKGROUND Outcome data comparing ischemic functional mitral
regurgitation (I-FMR) versus non-ischemic FMR (NI-FMR) following
percutaneous repair are not currently available in the literature. We
aimed to describe the early and 12-month results following MitraClip
device implantation regarding the two etiologies.
METHODS Between January 2011 December 2012 the Transcatheter Valve
Treatment Sentinel Pilot Registry included 452 patients with FMR who
underwent MitraClip procedure in 25 centers of 8 European countries.
RESULTS The prevalent etiology was I-FMR (235 patients, 52.0%). I-FMR
group had a signiﬁcant higher proportion of men (74.9 vs 59.9%, p<0.001)
and surgical risk (logistic EuroScore 24.818.2 vs 18.816.3, p<0.001).
Acute procedural success was high (95.8%) and similar between groups
(p¼0.48). Patients with I-FMR required a higher, albeit not signiﬁcant,
number of clips to reduce MR (p¼0.08). In-hospital mortality was low
(2.0%) without signiﬁcant differences between etiologies. Both I-FMR and
NI-FMR showed a signiﬁcant post-clip improvement in NYHA functional
class with the majority of patients exhibiting a NYHA class<II (82.6 and
74.2%, respectively). EuroSCORE,an impairedejection fraction (i.e.<30%),
pre-procedural chronic kidneydiseaseand the inability to reduce themitral
regurgitation represented the most important factors affecting both sur-
vival and re-hospitalization in FMR patients. Estimated overall 1-year
mortality and re-hospitalization rates were 15.0 and 25.8% respectively,
However, even though no signiﬁcant differences in terms of long-term
outcomeswere demonstrated, the survival curve showed a trend toward a
gradual decline in the I-FMR group versus a stabilization in the NI-FMR
group after 6 months. Paired echocardiographic data, available for 264
consecutive patients, showed a persistent improvement of MR at 1 year in
bothI-FMR and NI-FMR (6.6 and 5.4% of the patients with severe MR,
respectively). Despite a signiﬁcant overall reverse atrial remodeling after
clip, suggestive for an effective correction of the volume overload, no sig-
niﬁcate changes in left ventricular volumes have been demonstrated.
However, although both etiologies, showed a signiﬁcant acute decrease in
pulmonary pressure, only the I-FMR group demonstrated a concomitant
signiﬁcant acutedecrement inatrial volume (DLAV13.6ml,p¼0.016),while
at the 1-year follow-up a signiﬁcate reductionwas detected in both groups.
CONCLUSIONS This independent large cohort showed that percuta-
neous “edge-to-edge” therapy is associated with early and long-term
improvement of MR severity and functional status both in I-FMR and
NI-FMR groups. However some, albeit not signiﬁcant, differences
detectable both in the echocardiographic patterns and long-term
outcomes, suggest the possibility that the beneﬁt of Mitraclip differ
depending on the etiologies of mitral regurgitation prompting the
need for further large controlled studies investigating the underlying
pathogenetic mechanisms of FMR.
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